 ImmunityBio has finally submitted the Anktiva N-803 and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO. The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the outlook for these programs. 